In the Epizyme trial, the prevalence of EZH2 mutations among FL and DLBCL patients was 22.7% and 11.5% in DLBCL, respectively, with Y646F (previously Y641) being the most frequent mutation detected, as measured by the cobas EZH2 Test. Here, EZH2 is linked to diffuse large B-cell lymphoma.